PANCREATIC CYSTS

Up to 30% of cases remain indeterminate after EUS\(^1\)

Over 50% of cysts are inconclusive after FNA\(^2\)

60% of patients with benign pancreatic cysts undergo unnecessary surgery due to uncertain diagnoses\(^2\)

CELLVIZIO® CLINICAL VALUE

Improve characterization for indeterminate cysts\(^4\)

35% of patients with benign serous cystadenoma (SCA) prevented from further surveillance\(^4\)

23% reduction of surgical intervention\(^5\)

CELLVIZIO® CHARACTERIZATION OF CYSTS

REAL-TIME IN VIVO IMAGING AT THE CELLULAR LEVEL

Serous cystadenoma
Superficial vascular network

Mucinous cystadenoma
Epithelial border

IPMN
Papillary projection

NON-MUCINOUS

MUCINOUS

SEROUS CYSTADENOMA, MUCINOUS LESIONS

100% SPECIFICITY\(^6\)

95% SENSITIVITY\(^6\)

97% ACCURACY\(^6\)
INTEGRATE CELLVIZIO® INTO YOUR PRACTICE

“The specific signs of IPMN and serous cystadenoma seen with Cellvizio® allow me to make a formal decision on the nature of pancreatic cysts, avoiding unnecessary surgeries”
Dr. B. Napoléon,
Jean Mermoz Hospital

The diagnostic performance of nCLE significantly surpassed that of EUS and CEA titration for differentiating mucinous from non-mucinous lesions.6

“My approach to evaluating pancreatic cystic lesions is revolutionized, creating a major change in patient management”
Dr. C.J. DiMaio,
Mount Sinai Hospital and Mount Sinai Health System

IMPROVE PATIENT MANAGEMENT

DIAGNOSIS
More conclusive diagnosis4

OUTCOME

No follow-up: 28% modified therapeutic decision*

Surveillance: Eliminate surveillance of 35% of benign SCA4

Surgery: 23% reduction of surgical interventions5

AQ-Flex™ 19 Miniprobe

Compatible operating channel
≥ 0.91 mm

Length
3 m

Number of uses per probe
10

Field of view
Ø325 µm

Resolution
3.5 µm

Confocal depth
40 to 70 µm


Cellvizio® 100 Series Systems with Confocal Miniprobes™ are regulated Medical Device. CE marked (CE 0459) (Class Ia - NB: G-MED) and FDA cleared. Cellvizio® 100 Series Systems with Confocal Miniprobes™ are confocal laser systems with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells and vessels and their organization or architecture. Please consult labels and instructions for use. Product availability cannot be guaranteed in all countries. For further information, please contact your local sales representative. These statements and the associated reference to specific clinical studies, are not intended to represent claims of safety or effectiveness for detecting or treating any specific condition or disease state. Rather this information is intended to provide useful reference to selected published literature describing physician experiences with the associated clinical uses. Any diagnostic assessment should always be made by the attending physician, based on the evaluation of all sources of clinical, endoscopic and other relevant information. These statements have not been reviewed, cleared, or approved by the U.S. FDA. Once connected to the Cellvizio® 100 Series system, the AQ-Flex™ 19 Confocal Minprobe™ is intended to allow imaging of anatomical tracts, i.e., gastrointestinal tracts, accessed by an endoscope or endoscopic accessories, including through EUS-FNA needles. The use of this medical device is exclusively reserved for healthcare professionals.